XVIVO Q1 2023: Profitable growth - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

XVIVO Q1 2023: Profitable growth - Redeye

{newsItem.title}

XVIVO has performed well in 2023. Both the organic growth (35%) and the improved gross margins (74.5%) is well ahead of expectations and we expect a positive share price reaction of at least 5% vs the regional equity market. Our Base case of SEK 385 (our Bull is SEK 800 and our Bear case is SEK 105) ahead of Q1 2023.

Länk till analysen i sin helhet: https://www.redeye.se/research/896495/xvivo-q1-2023-profitable-growth?utm_source=finwire&utm_medium=RSS

Nyheter om Xvivo Perfusion

Läses av andra just nu

Om aktien Xvivo Perfusion

Senaste nytt